6 results about "Resistant infection" patented technology

Described herein is a synergistic combination comprising a quorum-sensing inhibitor and / or postbiotic metabolite and an antibiotic. Typically, the postbiotic metabolite comprises at least one peptide. Related compositions, uses, and methods are also described, including methods for resensitizing resistant bacteria to an antibiotic, and methods of treating antibiotic-resistant infections, such as methicillin-resistant Staphylococcus aureus (MRSA).

The invention discloses a betulinic acid derivative as well as a synthesis method and application thereof. According to the betulinic acid derivative, the carboxyl position of betulinic acid C-28 is subjected to structural modification, and four halogenated aniline derivatives are obtained. Wherein the derivatives b, d and e show strong activity on staphylococcus aureus, the derivatives d and e also show strong activity on vancomycin-resistant staphylococcus aureus (VRSA), and the derivative o strongly inhibits streptococcus pneumoniae. Compared with a parent skeleton, the four derivatives show significantly enhanced antibacterial efficacy. Experimental data prove that the derivatives d and e and further derivatives thereof may provide a promising strategy for resisting drug-resistant gram-positive pathogens, and the derivative d can be further developed into a novel therapeutic agent for biofilm-mediated drug-resistant infection.

The invention discloses an antigen protein as well as a preparation method and application thereof. The antigen protein comprises a soluble catalytic domain of the membrane protein LCP or a variant thereof. The antigen protein can be used for preventing and treating staphylococcus aureus infection, especially drug-resistant bacteria infection, and clinical related infectious diseases caused by the staphylococcus aureus infection, so that more stable broad-spectrum protection on staphylococcus aureus infection, especially drug-resistant staphylococcus aureus, is realized.

The present application belongs to the technical field of pharmaceutical chemistry, and particularly relates to an antibacterial small-molecule compound targeting bacterial phospholipid synthetase. The present application provides an antibacterial intervention strategy based on a novel mechanism of action, taking the key enzyme PlsY of bacterial specific membrane phospholipid synthesis as a target, and cracking the cross-resistance problem caused by the concentration of existing antibacterial drug targets. The lead compound T1 obtained by screening has strong inhibitory activity on PlsY, can effectively inhibit pathogenic bacteria such as Streptococcus pneumoniae and Staphylococcus aureus, and has better selective toxicity because the human body has no PlsY homologous protein. The compound has a novel structure and can be optimized, and can be rationally designed through structure-activity relationship, and also has inhibitory effect on plant pathogenic bacteria. The present application opens up a new antibacterial pathway, provides differentiated candidate molecules and reserves for coping with multi-drug resistant infections, and has medical and agricultural potential, and has significant innovation and practicality.

In one aspect, compounds and associated compositions are described herein for the treatment of various bacterial infections, including antibiotic resistant infections. In some embodiments, an antibacterial composition described herein comprises a dihydrofolate reductase inhibitor of Formula (I) and / or a salt thereof, and potentiator of the dihydrofolate reductase inhibitor of Formula (I). Moreover, in some embodiments, the antibacterial composition further comprises a thymine component, thereby enabling the antibacterial composition to selectively target bacterial species incapable of utilizing exogenous thymine.

The invention relates to an application of L-tryptophan in reversing T-2 toxin induced escherichia coli pan-drug resistance. T-2 toxin can induce Escherichia coli ATCC 25922 under the concentration of 10 ng / mL to generate pan-drug resistance, and failure to various antibiotics is difficult to deal with by the existing means. According to the invention, the L-tryptophan is exogenously added, so that the sensitivity of T-2 toxin induced pan-drug-resistant escherichia coli to beta-lactam antibiotics can be specifically recovered. The L-tryptophan is exogenously added, so that the content of bacterial biofilms can be reduced, and the sensitivity of bacteria to antibiotics can be improved. L-tryptophan is natural amino acid and is high in biocompatibility and low in toxicity, a foundation is laid for control of drug-resistant bacteria and reasonable use of antibiotics in a T-2 toxin pollution scene, drug-resistant bacteria transmission and antibiotic abuse can be reduced, higher safety and operability are achieved, and great significance is achieved on treatment of drug-resistant infection.